Back A A A Font Size Receive E-mail Alerts Press Releases

First Domestically Made World-Class Pacemaker Device Gains CFDA Approval


MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC"), a joint venture of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), recently gained the regulatory approval from China Food and Drug Administration ("CFDA") for its Rega™ Family Implantable Pacemakers, making them the first domestically made world-class pacemakers to gain market approval in China, which is expected to benefit more local patients with high quality and affordable price.
Rega™ Family Implantable Pacemakers has three series (Orchidee™, Trefle™, and Rega™) with a total of eight models. "They are all automatic, physiologic pacing pacemaker devices that feature small size and long life span. Specifically, they are the smallest pacemakers available in market with only eight cubic centimeters in volume, and they have service life of 10 to 12 years, allowing them to meet the need of various patients," said Dr. Li Wang, Chief Executive Officer of MSC and Fellow of Heart Rhythm Society, "With world-class quality and affordable price, it is expected that these pacemaker devices can provide safe, efficacious and cost-effective high-end solutions and service to physicians and patients in China."
Since its establishment in 2014, MSC has stuck to its vision of "Innovated in China, for China," and has been taking solid steps in becoming a company combining "Made-in-China" and "Innovated-in-China." MSC has built up a complete production chain by bringing in internationally advanced technology platform and following criteria of ISO13485 Quality Management System for Medical Devices. For example, according to the requirements of its production chain, every product of Rega™ Family Implantable Pacemakers is made after over 50 production procedures and more than 20 quality assessments, to achieve world-class quality and function. Aside from Rega™ Family Implantable Pacemakers, MSC is also developing cardiac pacemakers, pacing leads, and pacing system analyzers based on China's clinical needs, and is actively pushing forward the clinical and regulatory progress of these products featuring scientific designs and high quality.
Currently, implanting pacemakers is the only effective way to reduce mortality and improve life quality of patients with bradycardia. There are around one million patients suffering from bradycardia in China with an estimated 300,000 to 400,000 new cases annually. However, due to lack of core technologies and industrialization experience, China almost solely relies on imports for pacemaker devices, the high price of which has deterred most patients with only 80,000 of them can be treated with pacemakers each year.
Since its establishment, MSC has gained high recognition and strong support from Chinese Society of Pacing and Electrophysiology ("CSPE"), Chinese Society of Arrhythmias ("CSA" ), and domestic cardiac pacing and electrophysiological clinicians. With joint effort, they are committed to breaking the monopoly of imported pacemakers and revolutionizing China's pacemaker industry from "Made-in-China" to "Innovated-in-China" by developing the world's first-class pacemakers with advanced quality and technological innovation to benefit domestic patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Endovascular Attends 2017 Vascular Intervention of Peking University
[Next]:MicroPort® and MicroPort® Endovascular Attend CHC 2017